Akorn Pharmaceuticals

Akorn Investor Relations
Press Release
Printer Friendly Version  View printer-friendly version
<< Back
Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance

-Operational improvements drive sequential growth-

-Full year outlook anticipates further sequential growth throughout the year-

LAKE FOREST, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced its preliminary financial results for the first quarter of 2019.

First Quarter 2019 and Recent Business Highlights

  • Net revenue was $166 million, up 8% from the fourth quarter of 2018, down 10% from the prior year quarter
  • Net loss was $82 million, compared to $215 million in the fourth quarter of 2018 and $29 million in the prior year quarter
  • Adjusted EBITDA was $10 million, compared to ($20) million in the fourth quarter of 2018 and $25 million in the prior year quarter
  • Cash position of $184 million as of March 31, 2019
  • Full year 2019 guidance anticipates continued sequential improvement throughout the year 
  • Ongoing progress towards completion of FDA action items related to the inspections of our facilities in Decatur and Somerset
  • Further strengthening of leadership team and organizational capabilities
  • Significant reduction in backorders and failure to supply penalties
  • Two products launched year-to-date: Ropivacaine Hydrochloride Injection, USP (2mg/ml) and TheraTears® SteriLid® Antimicrobial, the 1st FDA Accepted Antimicrobial Eyelid Cleanser
  • Two New Product Approvals: Loteprednol Etabonate Ophthalmic Suspension, 0.5% and Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
  • Extended revolving credit facility and executed a Standstill Agreement with current lending institutions

See "Non-GAAP Financial Measures" below.

Douglas Boothe, Akorn’s President and Chief Executive Officer, stated, “We are pleased with the initial progress made across the organization executing against our operations, quality systems and compliance enhancement initiatives.  As a result, our first quarter financial results were stronger than anticipated and benefited from the resumption of full operations, improvement in product availability and strong demand across our diversified lines of business.  We believe that continued focus on these initiatives will provide us with a path to long-term, profitable growth.”

Boothe further commented, “As part of our confidence in our business fundamentals and in our ability to execute on the strategic growth objectives, we are providing guidance for the full year 2019.  We believe this is a strong step in the right direction as we get back to running our company with a freedom to operate and focus on creating value for our stakeholders.”

Summary Financial Results for the Quarter Ended March 31, 2019

Akorn reported net revenue of $165.9 million for the three month period ended March 31, 2019, representing a decrease of $18.2 million, or 9.9%, as compared to net revenue of $184.1 million for the three month period ended March 31, 2018.  The decrease in net revenue in the period was primarily due to $18.1 million decline in organic revenue that was partially offset by $0.7 million net revenue increase in new products and product relaunches.  The $18.1 million decline in organic revenue was due to approximately $30.5 million, or 16.6% in volume declines partially offset by $12.3 million, or 6.7%, of price variances.  The volume decline was principally due to the effect of competition on Ephedrine Sulfate Injection, Nembutal® and Cosopt® PF and supply shortfalls from the continued production ramp-up at our Somerset and Decatur manufacturing facilities.

Consolidated gross profit for the quarter ended March 31, 2019, was $53.5 million, or 32.3% of net revenue, compared to $82.2 million, or 44.7% of net revenue, in the corresponding prior year quarter.  The decline in the gross profit percentage was principally due to unfavorable product mix shifts primarily driven by the effect of competition on Ephedrine Sulfate Injection, Nembutal® and Cosopt®, unfavorable variances due to decreased production at our Somerset manufacturing facility, as well as increased operating costs associated with FDA compliance related improvement activities.

GAAP net loss for the first quarter 2019, was $82.2 million, or $(0.65) per diluted share, compared to GAAP net loss of $28.7 million, or $(0.23) per diluted share, for the same quarter of 2018.  Including a net adjustment of $70 million to net loss for non-GAAP items, adjusted diluted earnings per share for the first quarter 2019 were $(0.10), compared to $0.05 in the same quarter 2018, after a net adjustment of $35 million to net income for non-GAAP items.

Earnings before interest, taxes, depreciation and amortization (EBITDA) was $(47.7) million for the first quarter 2019, compared to $(6.2) million for the first quarter 2018.  Adjusted EBITDA, which is non-GAAP measure used by management to evaluate the continuing operations of the Akorn business, was $9.6 million for the first quarter 2019, compared to $24.5 million for the first quarter 2018.  See "Non-GAAP Financial Measures" below.

Fiscal 2019 Guidance

Duane Portwood, Akorn’s Chief Financial Officer, stated, “Our full year 2019 expectations anticipate building upon the momentum from the first quarter with sequential improvements expected over the course of the year, with the most significant contributions weighted towards the fourth quarter.”

Akorn's full year 2019 guidance:

  • Net revenue for the year expected to be in the range of $690 to $710 million
  • Net Loss expected in the range of ($166) to ($151) million
  • Adjusted EBITDA expected in the range of $71 to $86 million
  • Approximately $40 million in capital expenditures
  • Approximately $40 million for data integrity investigation and FDA compliance related expenditures

Standstill Agreement

We have been working constructively with our creditors and are pleased to have reached an agreement that is expected to provide Akorn time to continue to make progress on operational initiatives and deliver improved results, while also providing the lending institutions with additional transparency, reduced risk and enhanced protections.  For further information, we refer you to the Current Report on Form 8-K filed earlier today, which details the economic and non-economic terms of such agreement, including the covenants and other protections that we are providing to our lending institutions.

Status of Akorn Pending ANDA Filings, April 30, 2019:

In an effort to improve the efficiency of our future R&D spend, we have recently completed a review of our pending ANDAs and have decided to rationalize a number of pending filings.  Because of changes in the market size or competitive landscape, the expected commercial opportunity for these ANDAs no longer justifies further investment of time or funds required to obtain the approval.  The remaining pending ANDAs are summarized in the table below:

Filed     Tentative Approval Pending Total
values in millions     Count Value * Count Value * Count Value *
Ophthalmic Brand **   3        $455 10 $3,485 13 $3,940
  Generic   1   14 3   112 4   126
Injectable Brand **     2   11 2   11
  Generic   1   185 6   974 7   1,159
Topical Brand **        
  Generic     4   77 4   77
Other Brand **        
  Generic     7   340 7   340
Total     5         $654 32 $4,999 37 $5,653

*  The value, shown in millions, is the market size estimate based on IQVIA data for the trailing 12 months
 ended March 31, 2019 and excludes any trade and customary allowances and discounts.  The IQVIA market size is not a forecast of our future sales.

** The label "brand" indicates that the pending ANDA filing is for a product that has not yet had generic competition, therefore the market value is that of the branded reference drug.  All filings reported in the table are generic filings.

Conference Call and Webcast Details:
As previously announced, Akorn’s management will hold a conference call with interested investors and analysts at 10:00 a.m. EST on May 7, 2019, to discuss these results and updates in more detail.  The dial-in number to access the call is (844) 249-9382 in the U.S. and Canada and +1 (270) 823-1530 for international callers.  The conference ID is 8456549.  To access the live webcast, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.  A webcast replay of the conference call will be available shortly following the conclusion of the call and will be available for 90 days following the call.  To access the webcast replay, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.

About Akorn:
Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals.  Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals.  Additional information is available on Akorn’s website at www.akorn.com.

Non-GAAP Financial Measures:

To supplement Akorn’s financial results presented in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company uses certain non-GAAP (also referred to as “adjusted” or “non-GAAP adjusted”) financial measures in this press release and the accompanying tables, including (1) EBITDA, (2) adjusted EBITDA, (3) net debt, and (4) net debt to adjusted EBITDA ratio.  These non-GAAP measures adjust for certain specified items that are described in this release.  The Company believes that each of these non-GAAP financial measures is helpful in understanding its past financial performance and potential future results.  The non-GAAP financial measures are not meant to be considered in isolation or as a substitute for or superior to comparable GAAP measures.

Akorn’s management uses EBITDA, adjusted EBITDA, adjusted net income and adjusted diluted earnings per share in managing and analyzing its business and financial condition.  Akorn’s management believes that the presentation of these and other non-GAAP financial measures provide investors greater transparency into Akorn’s ongoing results of operations allowing investors to better compare the Company’s results from period to period.

Investors should note that these non-GAAP financial measures used to present financial guidance are not prepared under any comprehensive set of accounting rules or principles and do not reflect all of the amounts associated with the Company’s results of operations as determined in accordance with GAAP.  Investors should also note that these non-GAAP financial measures have no standardized meaning prescribed by GAAP and; therefore, have limits in their usefulness to investors.  In addition, from time-to-time in the future there may be other items that the Company may exclude for purposes of its non-GAAP financial measures; likewise, the Company may in the future cease to exclude items that it has historically excluded for purposes of its non-GAAP financial measures.  Because of the non-standardized definitions, the non-GAAP financial measures as used by Akorn in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by the Company’s competitors and other companies.

Set forth below is the definition of each non-GAAP financial measure as used by the Company in this press release and a full reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measures.

EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization.

Adjusted EBITDA, as defined by the Company, is calculated as follows:

Net (loss) income, (minus) plus:          

Interest income (expense), net
Provision for income taxes
Depreciation and amortization
Non-cash expenses, such as impairment of long-lived assets, share-based compensation expense, and amortization of deferred financing costs
Other adjustments, such as legal settlements, restatement expenses and various merger and acquisition-related expenses, employee retention expense, refinancing advisory fees, fixed asset impairment, executive termination expenses, data integrity investigations & assessment, gain on disposal of fixed assets, and
Fresenius transaction & litigation

Adjusted EBITDA is deemed by the Company to be a useful performance indicator because it includes an add back of non-cash or non-recurring operating expenses that have no impact on continuing cash flows as well as other items that are not expected to recur and therefore are not reflective of continuing operating performance.

Adjusted net (loss) income, as defined by the Company, is calculated as follows:

Net (loss) income, (minus) plus:
Amortization expense
Non-cash expenses, such as impairment of long-lived assets, share-based compensation expense, and amortization of deferred financing costs
Other adjustments, such as legal settlements, restatement expenses and various merger and acquisition-related expenses, employee retention expense, refinancing advisory fees, fixed asset impairment, executive termination expenses, data integrity investigations & assessment, gain on disposal of fixed assets, and
Fresenius transaction & litigation
Less an estimated tax provision, net of the benefit from utilizing net operating loss carry-forwards effected for the adjustments noted above

Adjusted diluted earnings per share, as defined by the Company, is equal to adjusted net income divided by the actual or anticipated diluted share count for the applicable period. The Company believes that adjusted net income and adjusted diluted earnings per share are meaningful financial indicators, to both Company management and investors, in that they exclude non-cash income and expense items that have no impact on current or future cash flows, as well as other income and expense items that are not expected to recur and therefore are not reflective of continuing operating performance.

The shortcomings of non-GAAP financial measures as guidance or performance measures are that they provide a view of the Company’s results of operations without including all events during a period.  For example, Adjusted EBITDA does not take into account the impact of capital expenditures on either the liquidity or the financial performance of the Company and likewise omits share-based compensation expenses, which may vary over time and may represent a material portion of overall compensation expense.  Adjusted net income does not take into account non-cash expenses that reflect the amortization of past expenditures, or include share-based compensation, which is an important and material element of the Company's compensation package for its directors, officers and other key employees.  Due to the inherent limitations of non-GAAP financial measures, investors should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.  Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures as presented in this press release.

Cautionary Note Regarding Forward-Looking Statements

This press release includes statements that may constitute "forward-looking statements", including expectations regarding the Company’s business plan and initiatives, the Company’s commitments to the FDA, disruptions during the Standstill Period and other statements regarding the Company’s plans and strategy. When used in this document, the words “will,” “expect,” “continue," “believe,” “anticipate,” “estimate,” “intend,” “could,” “strives” and similar expressions are generally intended to identify forward-looking statements. These statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Exchange Act. A number of important factors could cause actual results of the Company and its subsidiaries to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: (i) the effect of the Delaware court’s recent decision against the Company on the Company’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, or its operating results and business generally, (ii) the risk that ongoing or future litigation related to the court’s decision may result in significant costs of defense, indemnification and/or liability, (iii) the outcome of the investigation conducted by the Company with the assistance of outside consultants, into alleged breaches of FDA data integrity requirements relating to product development at the Company and any actions taken by the Company, third parties or the FDA as a result of such investigations, (iv) the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any, (v) the timing and success of product launches, (vi) difficulties or delays in manufacturing, (vii) the Company’s increased indebtedness and compliance with certain covenants and other obligations under the Standstill Agreement, which create material uncertainties and risks to its growth and business outlook, (viii) the Company’s obligation under the Standstill Agreement to enter into a Comprehensive Amendment that is satisfactory in form and substance to the Lenders, (ix) the Company’s obligation under the Standstill Agreement to pay certain fees and expenses and increased interest margin, (x) such other risks and uncertainties outlined in the risk factors detailed in Part I, Item 1A, “Risk Factors,” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (as filed with the Securities and Exchange Commission (“SEC”) on March 1, 2019), to be detailed in Part II, Item 1A, “Risk Factors,” of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019 (expected to be filed with the SEC by May 10, 2019) and other risk factors identified from time to time in the Company’s filings with the SEC. Readers should carefully review these risk factors, and should not place undue reliance on the Company’s forward-looking statements. These forward-looking statements are based on information, plans and estimates at the date of this press release. The Company undertakes no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.

AKORN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS)
(In Thousands, Except Per Share Data)
(Unaudited)

  Three Months Ended
March 31,
  2019   2018
Revenues, net 165,871     184,063  
Cost of sales (exclusive of amortization of intangibles, included within operating
expenses below)
112,358     101,835  
GROSS PROFIT 53,513     82,228  
Selling, general and administrative expenses 72,498     62,994  
Research and development expenses 8,714     12,644  
Amortization of intangibles 11,065     13,190  
Impairment of goodwill 15,955      
Impairment of intangible assets 10,354     18,815  
Litigation rulings and settlements 410      
TOTAL OPERATING EXPENSES 118,996     107,643  
OPERATING (LOSS) (65,483 )   (25,415 )
Amortization of deferred financing costs (1,304 )   (1,304 )
Interest expense, net (14,327 )   (9,578 )
Other non-operating income, net 353     270  
(LOSS) BEFORE INCOME TAXES (80,761 )   (36,027 )
Income tax provision (benefit) 1,420     (7,280 )
NET (LOSS) (82,181 )   (28,747 )
NET (LOSS) PER SHARE      
NET (LOSS) PER SHARE, BASIC (0.65 )   (0.23 )
NET (LOSS) PER SHARE, DILUTED (0.65 )   (0.23 )
SHARES USED IN COMPUTING NET (LOSS) PER SHARE      
BASIC 125,566     125,240  
DILUTED 125,566     125,240  
COMPREHENSIVE (LOSS)      
Net (loss) (82,181 )   (28,747 )
Unrealized holding (loss) on available-for-sale securities, net of tax of $0 for the three month period ended March 31, 2018.     (1 )
Foreign currency translation (loss) (424 )   (848 )
Pension liability adjustment (loss) gain, net of tax of $30 and ($1) for the three months ended March 31, 2019 and 2018, respectively. (116 )   4  
COMPREHENSIVE (LOSS) (82,721 )   (29,592 )

AKORN, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In Thousands, Except Share Data)

  March 31, 2019  (Unaudited)   December 31,
2018
ASSETS      
CURRENT ASSETS      
Cash and cash equivalents $ 184,090     $ 224,868  
Trade accounts receivable, net 174,325     153,126  
Inventories, net 162,752     173,645  
Prepaid expenses and other current assets 29,286     32,180  
TOTAL CURRENT ASSETS 550,453     583,819  
PROPERTY, PLANT AND EQUIPMENT, NET 325,970     334,853  
OTHER LONG-TERM ASSETS      
Goodwill 267,923     283,879  
Intangible assets, net 263,644     284,976  
Right-of-use assets, net - Operating leases 21,973      
Other non-current assets 7,228     7,730  
TOTAL OTHER LONG-TERM ASSETS 560,768     576,585  
TOTAL ASSETS $ 1,437,191     $ 1,495,257  
LIABILITIES AND SHAREHOLDERS’ EQUITY      
CURRENT LIABILITIES      
Trade accounts payable $ 38,419     $ 39,570  
Income taxes payable 13,925      
Accrued royalties 7,079     6,786  
Accrued compensation 16,529     19,745  
Accrued administrative fees 28,165     36,767  
Accrued legal fees and contingencies 49,710     52,413  
Current portion of lease liability - Operating leases 2,238      
Accrued expenses and other liabilities 12,721     15,542  
TOTAL CURRENT LIABILITIES 168,786     170,823  
LONG-TERM LIABILITIES      
Long-term debt (net of non-current deferred financing costs) 821,715     820,411  
Deferred tax liability 530     566  
FIN 48 reserve 51,410     49,990  
Long-term lease liability - Operating leases 21,480      
Pension obligations and other liabilities 7,521     9,601  
TOTAL LONG-TERM LIABILITIES 902,656     880,568  
TOTAL LIABILITIES 1,071,442     1,051,391  
SHAREHOLDERS’ EQUITY      
  Preferred stock, $1 par value - 5,000,000 shares authorized; no shares issued or outstanding at March 31, 2019 and December 31, 2018.      
  Common stock, no par value – 150,000,000 shares authorized; 125,578,913 and 125,492,373 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively. 579,157     574,553  
(Accumulated deficit) (189,349 )   (107,168 )
Accumulated other comprehensive (loss) (24,059 )   (23,519 )
TOTAL SHAREHOLDERS’ EQUITY 365,749     443,866  
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 1,437,191     $ 1,495,257  

AKORN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands)
(Unaudited)

  Three Months Ended
March 31,
  2019   2018
OPERATING ACTIVITIES:      
Net (loss) $ (82,181 )   $ (28,747 )
Depreciation and amortization 18,750     20,278  
Amortization of debt financing fees 1,304     1,304  
Impairment of intangible assets 10,354     18,815  
Goodwill impairment 15,955      
Fixed asset impairment and other 10,089      
Non-cash stock compensation expense 4,720     5,508  
Deferred income taxes, net (28 )   (7,833 )
Other (31 )   218  
Changes in operating assets and liabilities:      
Other non-current assets 584     37  
Trade accounts receivable (21,283 )   (35,508 )
Inventories, net 10,819     (9,292 )
Prepaid expenses and other current assets 1,079     11,997  
Trade accounts payable 722     11,318  
Accrued Legal Fees (2,703 )   (12,853 )
FIN 48 Reserve 1,420     512  
Accrued expenses and other liabilities (33 )   (7,345 )
NET CASH (USED IN) OPERATING ACTIVITIES $ (30,463 )   $ (31,591 )
INVESTING ACTIVITIES:      
Purchases of property, plant and equipment (10,059 )   (22,340 )
NET CASH (USED IN) INVESTING ACTIVITIES $ (10,059 )   $ (22,340 )
FINANCING ACTIVITIES:      
Proceeds from the exercise of stock options     546  
Stock compensation plan withholdings for employee taxes (116 )    
Payment of contingent acquisition liabilities     (4,793 )
Lease payments (335 )   (3 )
NET CASH (USED IN) FINANCING ACTIVITIES $ (451 )   $ (4,250 )
Effect of exchange rate changes on cash and cash equivalents 54     41  
 (DECREASE) IN CASH AND CASH EQUIVALENTS $ (40,919 )   $ (58,140 )
Cash and cash equivalents, and restricted cash at beginning of period 225,794     369,889  
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF PERIOD $ 184,875     $ 311,749  
SUPPLEMENTAL DISCLOSURES:      
Amount paid for interest $ 16,314     $ 12,262  
Amount (received) paid for income taxes, net $ (14,526 )   $ 8,205  
Additional capital expenditures included in accounts payable $ 4,641     $ 8,227  

Reconciliation of GAAP Net (Loss) to Non-GAAP EBITDA and Adjusted EBITDA
(In Thousands)
(Unaudited)

  Three Months Ended
    March 31,
    2019   2018
NET (LOSS) $ (82,181 )   $ (28,747 )
         
ADJUSTMENTS TO ARRIVE AT EBITDA:      
  Depreciation expense 7,685     7,088  
  Amortization expense 11,065     13,190  
  Interest expense, net 14,327     9,578  
  Income tax (benefit) provision 1,420     (7,280 )
EBITDA (47,684 )   (6,171 )
         
NON-CASH AND OTHER NON-RECURRING INCOME AND EXPENSES      
  Merger and acquisition-related expenses (3 )   11  
  Employee retention expense 1,612      
  Data integrity investigations & assessment 4,199     4,907  
  Fresenius transaction & litigation 2,147      
  Refinancing advisory fees 5,748      
  Non-cash stock compensation expense 4,720     5,508  
  Impairment of goodwill 15,955      
  Impairment of intangible assets 10,354     18,815  
  Amortization of deferred financing costs 1,304     1,304  
  Restatement expenses (26 )   90  
  Executive termination expenses 835      
  Impairment of fixed assets and other 10,089      
  Gain on disposal of fixed assets (31 )   (5 )
  Litigation rulings and settlements 410      
         
ADJUSTED EBITDA $ 9,629     $ 24,459  

The table below sets forth expenses included in Net (loss) that have not been included as adjustments to arrive at EBITDA and Adjusted EBITDA in the preceding table.

  ($ in thousands) 
  Three Months Ended
  March 31,
  2019   2018
FDA compliance related expenses $ 10,991     $  
Failure to supply penalties (recorded as a contra-revenue) $ 5,538     $ 9,473  
TheraTears® direct-to-consumer advertising campaign $ 2,651     $ 11,622  


Reconciliation of GAAP Net (Loss) to non-GAAP Adjusted Net (Loss) and Adjusted Diluted (Loss) Earnings Per Share
(In Thousands, Except Per Share Data)
(Unaudited)

  Three Months Ended
  March 31,
  2019   2018
NET (LOSS) $ (82,181 )   $ (28,747 )
       
Income tax provision (benefit) 1,420     (7,280 )
       
(LOSS) BEFORE INCOME TAXES $ (80,761 )   $ (36,027 )
       
ADJUSTMENTS TO ARRIVE AT ADJUSTED NET INCOME:      
Merger & acquisition-related expenses (1) (3 )   11  
Employee retention expense (2) 1,612      
Data integrity investigations & assessment (2) 4,199     4,907  
Fresenius transaction & litigation (2) 2,147      
Refinancing advisory fees (2) 5,748      
Restatement expenses (2) (26 )   90  
Non-cash stock compensation expense (2, 3, 4) 4,720     5,508  
Non-cash interest expense      
Amortization expense (5) 11,065     13,190  
Impairment of goodwill (7) 15,955      
Impairment of intangible assets (7) 10,354     18,815  
Amortization of deferred financing costs (8) 1,304     1,304  
Executive termination expenses (2) 835      
Impairment of fixed assets and other (9) 10,089      
Gain on disposal of fixed assets (2, 6) (31 )   (5 )
Litigation rulings and settlements (10) 410      
ADJUSTED (LOSS) INCOME BEFORE INCOME TAX $ (12,383 )   $ 7,793  
       
ADJUSTMENTS TO INCOME TAX PROVISION (BENEFIT)     1,575  
TOTAL ADJUSTED INCOME TAX PROVISION (BENEFIT) $     $ 1,575  
       
ADJUSTED NET (LOSS)  INCOME $ (12,383 )   $ 6,218  
       
ADJUSTED DILUTED EARNINGS PER SHARE $ (0.10 )   $ 0.05  
       
(1) - Excluded from Acquisition-related costs      
(2) - Excluded from SG&A expenses      
(3) - Excluded from R&D expenses      
(4) - Excluded from Cost of sales      
(5) - Excluded from Amortization of intangibles      
(6) - Excluded from Other non-operating (expense) income, net      
(7) - Excluded from Impairment of goodwill, intangible assets      
(8) - Excluded from Amortization of deferred financing costs      
(9) - Excluded from Impairment of fixed assets      
(10) - Excluded from Litigation rulings and settlements      


AKORN, INC.
Reconciliation of GAAP Debt to Non-GAAP Net Debt and Net Debt to Adjusted EBITDA Ratio
(In Thousands, Except Net Debt to Adjusted EBITDA Ratio)

  March 31, 2019
GAAP Debt $ 821,715  
Deferred financing costs 10,223  
Total term loans outstanding $ 831,938  
Cash and cash equivalents 184,090  
  Net debt (1) $ 647,848  
   
Adjusted EBITDA, trailing twelve months ended $ 34,452  
   
Net debt to adjusted EBITDA ratio (2) 18.8  

(1) Net debt, as defined by the Company, is gross debt including Akorn’s term loan and revolving debt balances (if applicable) less cash and cash equivalents.

(2) Net debt to Adjusted EBITDA ratio, as defined by the Company, is net debt divided by the trailing twelve months Adjusted EBITDA.

AKORN, INC.
Reconciliation of 2019 Financial Guidance of GAAP Net Loss to Non-GAAP Adjusted EBITDA
(In Millions)

  2019 Guidance
  Lower Range   Upper Range
NET (LOSS) $ (166 )   $ (151 )
       
Add:      
Depreciation expense 32     32  
Amortization expense 40     40  
Interest expense, net 58     58  
Income tax (benefit) provision 6     6  
EBITDA $ (30 )   $ (15 )
       
Add:      
Employee retention expense 6     6  
Data Integrity investigations & assessment 10     10  
Fresenius transaction & litigation 6     6  
Non-cash stock compensation expense 21     21  
Refinancing advisory fees 15     15  
Impairment of goodwill 16     16  
Impairment of intangible assets 10     10  
Amortization of deferred financing costs 5     5  
Executive termination expenses 1     1  
Impairment of fixed assets and other 10     10  
Litigation rulings and settlements 1     1  
       
ADJUSTED EBITDA $ 71     $ 86  

Investors/Media:
(847) 279-6162
Investor.relations@akorn.com 

AkornLogoSOLID_.jpg

Source: Akorn, Inc.